At present, a few subgroups of clinical trials have reported the comparison between immune checkpoint inhibitors and chemotherapy in patients with different molecular characteristics, such as PD-L1 protein expression,[7] EGFR gene expression,[8,9] tumor mutational burden (TMB),[10] and so on. The gene discussed is EGFR; the disease is neoplasm.